| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TGF beta 1 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
 N Y (what is this?) (verify) | |
Metelimumab (CAT-192) is a humanIgG4monoclonal antibody that neutralizesTGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemicsclerosis, also known asscleroderma.[1] It was dropped from further development in favour offresolimumab,[2] which was being developed byGenzyme as of 2006.[3]
Metelimumab was isolated byCambridge Antibody Technology (CAT) using itsphage display technology. In 2000, CAT signed a collaborative deal with Genzyme to further developTGF beta antibodies.[4][5]
In 2004, CAT and Genzyme revealed that Phase I/II trials of metelimumab for scleroderma showed this antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.[6]
Initial trials targeted the skin conditionscleroderma[7] but, after some unsuccessful clinical trial results, the product was dropped in favour of fresolimumab,[2] which was being developed by Genzyme as of 2006.[3]
{{cite journal}}:Cite journal requires|journal= (help) | Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it. |
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |